7月16日,在科兴生物美股退市警报拉响之际,市场传出其正谋求港股上市的消息。这家曾凭借新冠疫苗一度比肩辉瑞的疫苗巨头,正在资本市场的夹缝中寻找生机。然而,长达十年的内斗已让科兴生物遍体鳞伤——从抢公章、剪电线的荒诞闹剧,到“毒丸计划”“清盘式分红”的资本博弈,每一次权力交锋,都在加速消耗这家疫苗巨头。“这不仅是股权设计缺陷引发的治理灾难,更是资本博弈的恶果。”一级市场投资人李伟冉对《法人》记者坦言...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.